A recent wave of research in psychiatry and neuroscience has re-examined the properties of “classic” psychedelic substances - also known as serotonergic hallucinogens - such as psilocybin, LSD, and DMT. Evidence to date suggests that psychedelics can be given safely in controlled conditions, at moderate to high doses, and may have potential as therapeutic agents in the treatment of various addictive and mood disorders. The main mechanism of action appears to be the induction of a dramatically altered state of consciousness, but the details of how psychedelic-assisted psychotherapy works are hotly debated, as are the relations between psychedelic experiences themselves and the neural changes induced by the drugs. Philosophical Perspectives on Psychedelic Psychiatry addresses the fascinating philosophical questions raised by the renewed psychiatric use of psychedelics, with chapters from leading philosophers of mind, science, and psychiatry centred around three main themes. Chapters in the “self and mind” section ask: what can we learn about the self and the mind from psychedelic science? Chapters in the “science and psychiatry” section address methodological, theoretical, and clinical questions concerning how psychedelics can best be studied scientifically and used therapeutically, and how they might work to relieve psychiatric suffering. Finally, chapters in the “ethics and spirituality” section address broader questions about the interpretation of psychedelic experience, its ethical implications, and its possible role(s) in the broader culture.

This Handbook provides a comprehensive overview and analysis of the state of the field of the philosophy of meditation and engages primarily in the philosophical assessment of the merits of meditation practices. This Handbook unites novel and original scholarship from 28 leading Asian and Western philosophers, scientists, theologians, and other scholars on the philosophical assessment of meditation. It critically assesses the conceptual and empirical validity of meditation, its philosophical implications, its legitimacy as a phenomenological research tool, its potential value as an aid to neuroscience research, its many practical benefits, and, among other considerations, its possibly misleading interpretations, applications, and consequences. Following the introduction by the editor, the Handbook’s chapters are organized in six parts: • Meditation and philosophy • Meditation and epistemology • Meditation and metaphysics • Meditation and values • Meditation and phenomenology • Meditation in Greco-Roman and Judeo-Christian traditions A distinctive, timely, and invaluable reference work, it marks the emergence of a new discipline therein, the philosophy of meditation. The book will be of interest to an interdisciplinary audience in the fields of philosophy, meditation, Buddhism, Hinduism, Taoism, theology, and Asian and Western philosophy. It will serve as the textbook in any philosophy course on meditation, and as secondary reading in courses in philosophy of mind, consciousness, selfhood/personhood, metaphysics, or phenomenology, thereby helping to restore philosophy as a way of life.

LSD's short but colorful history in North America carries with it the distinct cachet of counterculture and government experimentation. The truth about this mind-altering chemical cocktail is far more complex—and less controversial—than generally believed. Psychedelic Psychiatry is the tale of medical researchers working to understand LSD’s therapeutic properties just as escalating anxieties about drug abuse in modern society laid the groundwork for the end of experimentation at the edge of psychopharmacology. Historian Erika Dyck deftly recasts our understanding of LSD to show it as an experimental substance, a medical treatment, and a tool for exploring psychotic perspectives—as well as a recreational drug. She recounts the inside story of the early days of LSD research in small-town, prairie Canada, when Humphry Osmond and Abram Hoffer claimed incredible advances in treating alcoholism, understanding schizophrenia and other psychoses, and achieving empathy with their patients. In relating the drug’s short, strange trip, Dyck explains how concerns about countercultural trends led to the criminalization of LSD and other so-called psychedelic drugs—concordantly opening the way for an explosion in legal prescription pharmaceuticals—and points to the recent re-emergence of sanctioned psychotropic research among psychiatric practitioners. This challenge to the prevailing wisdom behind drug regulation and addiction therapy provides a historical corrective to our perception of LSD’s medical efficacy.

This book is the first scholarly monograph in English devoted to the philosophical analysis of psychedelic drugs. Its central focus is the apparent conflict between the growing use of psychedelics in psychiatry and the philosophical worldview of naturalism.

Psychedelics are part of a resurgence of interest in consciousness studies, especially as altered states of consciousness are being re-examined in the context of psychedelic-assisted therapies. To date, discussions about psychedelics in modern medicine have been dominated by studies in biomedicine. However, given that cultural factors play a significant role in the subjective effects of psychedelics, psychedelics can be considered a uniquely powerful point of convergence between the cultural and biomedical. Writers and artists, alongside psychiatrists and pharmacologists, have participated in shaping ‘the psychedelic experience’ by drawing on a rich set of approaches that blend narrative, arts, and humanities concepts to explain and interpret psychedelic experiences and explore consciousness for creative purposes. Psychedelic studies, past and present, emphasize the importance of ‘set and setting’ or the context of psychedelic consumption and its paramount importance in shaping psychedelic experiences. These non-pharmacological factors rely on a different set of methods and interpretations that necessarily rely on studies conducted outside of the biomedical sciences.

The rise—and fall—of research into the therapeutic potential of LSD. After LSD arrived in the United States in 1949, the drug's therapeutic promise quickly captured the interests of psychiatrists. In the decade that followed, modern psychopharmacology was born and research into the drug's perceptual and psychological effects boomed. By the early 1960s, psychiatrists focused on a particularly promising treatment known as psychedelic therapy: a single, carefully guided, high-dose LSD session coupled with brief but intensive psychotherapy. Researchers reported an astounding 50 percent success rate in treating chronic alcoholism, as well as substantial improvement in patients suffering from a range of other disorders. Yet despite this success, LSD officially remained an experimental drug only. Research into its effects, psychological and otherwise, dwindled before coming to a close in the 1970s. In The Trials of Psychedelic Therapy, Matthew Oram traces the early promise and eventual demise of LSD psychotherapy in the United States. While the common perception is that LSD's prohibition terminated legitimate research, Oram draws on files from the Food and Drug Administration and the personal papers of LSD researchers to reveal that the most significant issue was not the drug's illegality, but the persistent question of its efficacy. The landmark Kefauver-Harris Drug Amendments of 1962 installed strict standards for efficacy evaluation, which LSD researchers struggled to meet due to the unorthodox nature of their treatment. Exploring the complex interactions between clinical science, regulation, and therapeutics in American medicine, The Trials of Psychedelic Therapy explains how an age of empirical research and limited government oversight gave way to sophisticated controlled clinical trials and complex federal regulations. Analyzing the debates around how to understand and evaluate treatment efficacy, this book will appeal to anyone with an interest in LSD and psychedelics, as well as mental health professionals, regulators, and scholars of the history of psychiatry, psychotherapy, drug regulation, and pharmaceutical research and development.

What do psychedelics reveal about consciousness? What impact have psychedelics had on philosophy? In this rapidly growing area of study, this is the first volume to explore the philosophy of psychedelic experience, from a range of interdisciplinary and cross-cultural perspectives. In doing so, Philosophy and Psychedelics reveals just why the place of psychedelics in our societies should not be left to medical sciences alone, as psychedelic experience opens up new perspectives on fundamental philosophical questions relating to human experience, ethics, and the metaphysics of mind. Mapping a range of philosophical responses to the surge in studies into psychedelic drugs in the cognitive sciences, this go-to volume examines topics including psychedelics and the role of governance; psychedelics and mysticism; what psychedelics can tell us about dyadic thankfulness; and psychedelics as ways to gain new knowledge. Written by leading international scholars, the essays cover Western and non-Western traditions, from analytic philosophy to Zen Buddhism, and discuss a variety of hallucinogens, such as LSD, MDMA, and Ayahuasca, in order to build a much-needed bridge between the rapidly growing scientific research and the philosophy behind psychedelic experience.

Psychedelic therapies are gaining traction as potential treatments for a wide range of indications, but the structure and delivery of psychedelic therapies are a sharp departure from more traditional models of psychotherapy and pharmacotherapy for psychiatric and other medical disorders. This may be critical to their success. The current volume provides a comprehensive review of the state of the science of psychedelic therapies, including discussion of models and approaches to psychedelic therapies as well as the current status of safety and efficacy data for mood, substance use, trauma, obsessive-compulsive, neurodevelopmental, neurodegenerative disorders, neurological, and inflammatory disorders.